Literature DB >> 3114041

[Gonadotropin stimulation and in vitro fertilization following selective hypophyseal suppression by LH/RH analogs].

C Lindner, W Braendle, L Bispink, V Lichtenberg, G Bettendorf.   

Abstract

Out of 109 hMG stimulations for in vitro fertilization (IVF) 41 cycles (38%) had to be cancelled because of premature endogenous luteinization. Pretreatment with the LH/RH-agonist Buserelin induces selective pituitary suppression and prevents spontaneous LH-surge during hMG stimulation. The pharmacologic hypogonadotropism allows considerable flexibility with respect to the timing of starting gonadotropin stimulation and ovulation induction. In 74 Buserelin/hMG/IVF-cycles no premature luteinization occurred and all started stimulations yielded in follicular puncture. In addition increased oocyte recovery rate, significant higher fertilization rate and significant better pregnancy rate could be achieved as compared with hMG/IVF-cycles. In conclusion pharmacologic hypogonadotropism by administration of LH/RH-analogue reliably prevents endogenous luteinization and improves gonadotropin stimulation as well as IVF results.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114041     DOI: 10.1055/s-2008-1035859

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  4 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  [Combined GnRH agonist/hMG therapy and ovarian overstimulation syndrome].

Authors:  C Lindner; W Braendle; V Lichtenberg; G Bettendorf
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  [Spontaneous endogenous LH increase in the stimulated cycle].

Authors:  H Alexander; M Birkhäuser; G Zimmermann; P Huber; N Pavic; M Lehmann; D Baier; W Weber; K W Haake
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone.

Authors:  A J Rutherford; R J Subak-Sharpe; K J Dawson; R A Margara; S Franks; R M Winston
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.